NCT04751383 - Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2021

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions

High Risk NeuroblastomaRecurrent NeuroblastomaRecurrent OsteosarcomaRefractory NeuroblastomaResectable Osteosarcoma

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Computed Tomography

Undergo CT

BIOLOGICAL

Dinutuximab

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

BIOLOGICAL

Magrolimab

Given IV

PROCEDURE

Resection

Undergo surgical resection

Trial Locations (11)

19104

Children's Hospital of Philadelphia, Philadelphia

60637

University of Chicago Comprehensive Cancer Center, Chicago

77030

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston

80045

Children's Hospital Colorado, Aurora

90027

Children's Hospital Los Angeles, Los Angeles

94158

UCSF Medical Center-Mission Bay, San Francisco

94304

Lucile Packard Children's Hospital Stanford University, Palo Alto

98105

Seattle Children's Hospital, Seattle

02215

Dana-Farber Cancer Institute, Boston

V6H 3V4

British Columbia Children's Hospital, Vancouver

M5G 1X8

Hospital for Sick Children, Toronto

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH